Research Paper Volume 14, Issue 5 pp 2335—2347

Figure 1. Comparison of clinical manifestations at different doses of 3-NPA. (A, B) 3-NPA had no significant effects on body weight. (C) 3-NPA could prolong the mean length of the diestrus phase and decrease the mean length of the estrous phase after two weeks of treatment, especially when used at a dose of 50 mg/kg. (D) 3-NPA could prolong the mean length of the diestrus phase and decrease the mean length of the estrous phase after three weeks of treatment, especially when used at a dose of 40 mg/kg and 50 mg/kg. (E, F) 3-NPA reduced the ovarian index, especially when used at a dose of 40 mg/kg and 50 mg/kg. (G, H) Serum E₂ concentration in different groups; mice treated with 40 mg/kg 3-NPA for 3 weeks and those treated with 50 mg/kg 3-NPA for 2 or 3 weeks showed a significant decrease. (I, J) Serum FSH concentration in the different groups; mice treated with 40 mg/kg or 50 mg/kg 3-NPA for 3 weeks showed a significant increase. (K, L) Serum AMH concentration in different groups; mice treated with 40 mg/kg 3-NPA for 3 weeks and those treated with 50 mg/kg 3-NPA for 2 or 3 weeks showed a significant decrease. (M) In the mice treated with 50 mg/kg 3-NPA for 2 weeks, the number of primordial follicles decreased. (N) In the mice treated with 40 mg/kg or 50 mg/kg 3-NPA for 3 weeks, the number of primordial follicles decreased, the number of atretic follicles increased, and the number of growing follicles did not change significantly. (N=8 in all assays; *P<0.05, **P<0.01, and ***P<0.001 compared with the control group, NS: none significant).